Managed Care Strategies to Support Access to CAR T-Cell Therapy
On-Demand 1-hour Accredited Webcast
Kite Pharma, Inc.
Faculty Presenter
Rebecca Borgert, PharmD, BCOP
Senior Director, Oncology Clinical Strategy and Innovation
Magellan Rx Management
Gainesville, Florida
Program Description
While just 3 chimeric antigen receptor-modified T cell (CAR T-cell) therapies for hematologic malignancies are commercially available, recent years have seen rapid and increased research into these therapies for multiple indications. The production and administration of CAR T-cell therapy can be complex as each product is patient-specific and can require weeks to manufacture with multidisciplinary coordination. Pharmacists must be familiar with guideline recommendations for treatment of CAR-related adverse effects, such as cytokine release syndrome (CRS), and be proactive in ensuring protocols and resources are established for their management. Each of these factors contributes to the high cost of CAR T-cell therapy, which can average up to $1.5 million per patient, though cost-effectiveness analyses suggest these therapies may have a cost-benefit over traditional chemotherapy. Equipped with clinical information regarding safety and efficacy of CAR T-cell therapies, managed care pharmacists can promote their integration of these therapeutics into management strategies that may reduce associated costs, decrease hospitalization, and improve outcomes for patients.
Target Audience: Managed care and oncology pharmacists
Type of Activity: Application
Release date: June 10, 2021
Expiration date: June 10, 2022
Time to complete activity: 1 hour
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Examine recent studies for approved and emerging chimeric antigen receptor-modified T cell (CAR) T-cell therapies and the impact of these treatments on the future paradigm of cancer care
- Characterize costs associated with CAR T-cell therapy, particularly in the prevention and treatment of adverse effects
- Identify strategies to improve management of costs associated with CAR T-cell therapy
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-21-243-H01-P. The activity is available for CE credit through June 10, 2022.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, view the webcast in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
Rebecca Borgert, PharmD, BCOP, has the following relevant financial relationships with commercial interests to disclose:
- Consultant: Seagen
- Spouse: Employee of Melinta Therapeutics
Medical Reviewer
Scott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA, has the following relevant financial relationships with commercial interests to disclose:
- Grants/Research Support: AstraZeneca, Janssen
- Consultant: AstraZeneca, G1 Therapeutics, Spectrum Pharmaceuticals, Sun Pharma
- Speakers Bureau: Pfizer
Pharmacy Times Continuing Education™ Planning Staff – Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Amy H. Seung, PharmD, BCOP, FHOPA; Crissy Wilson; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with commercial interests to disclose.
An anonymous peer reviewer is used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
Privacy Policy and Terms of Use Information:
